The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now ...

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

is that C. difficile is evolving to resist vancomycin. "We don't know if there are resistant strains circulating and causing ...

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

A new study published today in the American Journal of Infection Control (AJIC) describes the outcome of a new approach to ...

With no approved vaccines to date, C. diff causes nearly 30,000 deaths each year in the US, and recurrent infections with the bacterium make up 10%-15% of all hospital-treated infections.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

Pfizer has been working on a potential vaccine for C. diff, but its first attempt missed ... updated formulation through mid-stage clinical testing. In the phase 3 ECOSPOR trial, patients who ...

Medscape Medical News, May 24, 2022 Understanding Toxin Testing Results for C diff Testing stool samples for C difficile exotoxins A and B is frequently used to diagnose a C difficile infection ...

An advantage of CRS3123 compared with other treatments is its narrow spectrum, which targets C. difficile bacteria and stops toxin production while minimally affecting other microbes in the gut.

H. pylori infections occur across the world due to exposure to saliva or stool in contaminated water or food. Learn how the ...